OPNT Annual EBIT
$5.16 M
+$7.32 M+339.41%
31 December 2021
Summary:
As of February 5, 2025, OPNT annual earnings before interest & taxes is $5.16 million, with the most recent change of +$7.32 million (+339.41%) on December 31, 2021. During the last 3 years, it has risen by +$26.35 million (+124.36%).OPNT EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OPNT Quarterly EBIT
-$9.52 M
+$1.79 M+15.80%
30 September 2022
Summary:
As of February 5, 2025, OPNT quarterly earnings before interest & taxes is -$9.52 million, with the most recent change of +$1.79 million (+15.80%) on September 30, 2022. Over the past year, it has dropped by -$13.48 million (-340.07%).OPNT Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OPNT TTM EBIT
-$31.31 M
-$13.48 M-75.63%
30 September 2022
Summary:
As of February 5, 2025, OPNT TTM earnings before interest & taxes is -$31.31 million, with the most recent change of -$13.48 million (-75.63%) on September 30, 2022. Over the past year, it has dropped by -$34.17 million (-1193.30%).OPNT TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OPNT EBIT Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +339.4% | -340.1% | -1193.3% |
3 y3 years | +124.4% | -189.8% | -374.3% |
5 y5 years | +234.8% | -69.8% | -374.3% |
OPNT EBIT High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | ||||||
5 y | 5-year | ||||||
alltime | all time | -55.7% | -189.5% | -369.9% |
Opiant Pharmaceuticals EBIT History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2022 | - | -$9.52 M(-15.8%) | -$31.31 M(+75.6%) |
June 2022 | - | -$11.30 M(-3.9%) | -$17.83 M(+314.8%) |
Mar 2022 | - | -$11.77 M(-1019.8%) | -$4.30 M(-183.3%) |
Dec 2021 | $5.16 M(-339.4%) | $1.28 M(-67.7%) | $5.16 M(+80.3%) |
Sept 2021 | - | $3.96 M(+78.1%) | $2.86 M(-862.0%) |
June 2021 | - | $2.23 M(-196.5%) | -$375.80 K(-86.7%) |
Mar 2021 | - | -$2.31 M(+126.4%) | -$2.82 M(+30.7%) |
Dec 2020 | -$2.16 M(-118.9%) | -$1.02 M(-240.6%) | -$2.16 M(-2215.8%) |
Sept 2020 | - | $725.00 K(-435.3%) | $101.90 K(-99.0%) |
June 2020 | - | -$216.20 K(-86.9%) | $9.97 M(-14.0%) |
Mar 2020 | - | -$1.65 M(-232.8%) | $11.60 M(+1.6%) |
Dec 2019 | $11.42 M(-153.9%) | $1.24 M(-88.3%) | $11.42 M(+1951.3%) |
Sept 2019 | - | $10.60 M(+651.7%) | $556.50 K(-105.1%) |
June 2019 | - | $1.41 M(-177.1%) | -$10.98 M(-19.9%) |
Mar 2019 | - | -$1.83 M(-81.0%) | -$13.71 M(-35.3%) |
Dec 2018 | -$21.19 M(-1474.2%) | -$9.62 M(+923.4%) | -$21.19 M(+83.1%) |
Sept 2018 | - | -$940.00 K(-28.9%) | -$11.57 M(-28.7%) |
June 2018 | - | -$1.32 M(-85.8%) | -$16.24 M(+10.3%) |
Mar 2018 | - | -$9.31 M(+66.0%) | -$14.71 M(-812.3%) |
Dec 2017 | $1.54 M(-78.3%) | - | - |
Oct 2017 | - | -$5.61 M(-2911.4%) | $2.07 M(-70.9%) |
July 2017 | $7.09 M(-191.7%) | $199.40 K(-106.3%) | $7.09 M(+21.4%) |
Apr 2017 | - | -$3.17 M(-129.8%) | $5.84 M(-38.0%) |
Jan 2017 | - | $10.64 M(-1937.3%) | $9.42 M(+238.4%) |
Oct 2016 | - | -$579.00 K(-44.9%) | $2.78 M(-136.0%) |
July 2016 | -$7.74 M(+10.4%) | -$1.05 M(-355.1%) | -$7.74 M(-7.1%) |
Apr 2016 | - | $411.90 K(-89.7%) | -$8.33 M(-21.3%) |
Jan 2016 | - | $4.00 M(-136.0%) | -$10.58 M(-39.0%) |
Oct 2015 | - | -$11.10 M(+577.4%) | -$17.34 M(+147.6%) |
July 2015 | -$7.01 M(-38.1%) | -$1.64 M(-11.0%) | -$7.00 M(-26.4%) |
Apr 2015 | - | -$1.84 M(-33.2%) | -$9.51 M(+15.7%) |
Jan 2015 | - | -$2.76 M(+259.3%) | -$8.21 M(-21.8%) |
Oct 2014 | - | -$767.10 K(-81.5%) | -$10.51 M(-7.2%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
July 2014 | -$11.32 M(+31.3%) | -$4.14 M(+657.9%) | -$11.33 M(+35.5%) |
Apr 2014 | - | -$546.90 K(-89.2%) | -$8.36 M(-0.4%) |
Jan 2014 | - | -$5.05 M(+217.9%) | -$8.39 M(-11.9%) |
Oct 2013 | - | -$1.59 M(+34.8%) | -$9.53 M(+10.1%) |
July 2013 | -$8.62 M(-30.2%) | -$1.18 M(+103.3%) | -$8.65 M(-4.7%) |
Apr 2013 | - | -$579.60 K(-90.6%) | -$9.08 M(-8.9%) |
Jan 2013 | - | -$6.18 M(+768.2%) | -$9.97 M(+19.2%) |
Oct 2012 | - | -$711.90 K(-55.8%) | -$8.37 M(-32.3%) |
July 2012 | -$12.36 M(+31.0%) | -$1.61 M(+9.5%) | -$12.36 M(-8.5%) |
Apr 2012 | - | -$1.47 M(-67.9%) | -$13.51 M(-22.5%) |
Jan 2012 | - | -$4.57 M(-2.8%) | -$17.44 M(+25.8%) |
Oct 2011 | - | -$4.71 M(+70.5%) | -$13.86 M(+46.9%) |
July 2011 | -$9.44 M(+367.9%) | -$2.76 M(-48.9%) | -$9.44 M(+31.8%) |
Apr 2011 | - | -$5.40 M(+442.8%) | -$7.16 M(+261.9%) |
Jan 2011 | - | -$994.70 K(+253.0%) | -$1.98 M(-11.0%) |
Oct 2010 | - | -$281.80 K(-41.8%) | -$2.22 M(+10.2%) |
July 2010 | -$2.02 M(>+9900.0%) | -$484.40 K(+122.8%) | -$2.02 M(+31.5%) |
Apr 2010 | - | -$217.40 K(-82.5%) | -$1.53 M(+16.1%) |
Jan 2010 | - | -$1.24 M(+1525.7%) | -$1.32 M(+1445.0%) |
Oct 2009 | - | -$76.20 K(+4382.4%) | -$85.50 K(+481.6%) |
July 2009 | -$14.70 K(-17.9%) | -$1700.00(-60.5%) | -$14.70 K(-41.2%) |
Apr 2009 | - | -$4300.00(+30.3%) | -$25.00 K(+10.6%) |
Jan 2009 | - | -$3300.00(-38.9%) | -$22.60 K(0.0%) |
Oct 2008 | - | -$5400.00(-55.0%) | -$22.60 K(+26.3%) |
July 2008 | -$17.90 K(-46.7%) | -$12.00 K(+531.6%) | -$17.90 K(-0.6%) |
Apr 2008 | - | -$1900.00(-42.4%) | -$18.00 K(-15.1%) |
Jan 2008 | - | -$3300.00(+371.4%) | -$21.20 K(+14.6%) |
Oct 2007 | - | -$700.00(-94.2%) | -$18.50 K(-29.4%) |
July 2007 | -$33.60 K | -$12.10 K(+137.3%) | -$26.20 K(+85.8%) |
Apr 2007 | - | -$5100.00(+750.0%) | -$14.10 K(+48.4%) |
Jan 2007 | - | -$600.00(-92.9%) | -$9500.00(+6.7%) |
Oct 2006 | - | -$8400.00(+1580.0%) | -$8900.00(+1680.0%) |
Apr 2006 | - | -$500.00(<-9900.0%) | -$500.00(<-9900.0%) |
Jan 2006 | - | $0.00 | $0.00 |
FAQ
- What is Opiant Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Opiant Pharmaceuticals?
- What is Opiant Pharmaceuticals annual EBIT year-on-year change?
- What is Opiant Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Opiant Pharmaceuticals?
- What is Opiant Pharmaceuticals quarterly EBIT year-on-year change?
- What is Opiant Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Opiant Pharmaceuticals?
- What is Opiant Pharmaceuticals TTM EBIT year-on-year change?
What is Opiant Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of OPNT is $5.16 M
What is the all time high annual EBIT for Opiant Pharmaceuticals?
Opiant Pharmaceuticals all-time high annual earnings before interest & taxes is $11.65 M
What is Opiant Pharmaceuticals annual EBIT year-on-year change?
Over the past year, OPNT annual earnings before interest & taxes has changed by +$7.32 M (+339.41%)
What is Opiant Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of OPNT is -$9.52 M
What is the all time high quarterly EBIT for Opiant Pharmaceuticals?
Opiant Pharmaceuticals all-time high quarterly earnings before interest & taxes is $10.64 M
What is Opiant Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, OPNT quarterly earnings before interest & taxes has changed by -$13.48 M (-340.07%)
What is Opiant Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of OPNT is -$31.31 M
What is the all time high TTM EBIT for Opiant Pharmaceuticals?
Opiant Pharmaceuticals all-time high TTM earnings before interest & taxes is $11.60 M
What is Opiant Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, OPNT TTM earnings before interest & taxes has changed by -$34.17 M (-1193.30%)